Glycerylnitrat

Glycerylnitrat, containing the active ingredient glyceryl trinitrate, is a prescription intravenous medication used in the European market. It belongs to the nitrate vasodilator class and works by releasing nitric oxide to relax blood vessels. The product is administered under medical supervision and is indicated for specific cardiovascular emergencies. Its formulation is designed for rapid onset of action in acute care settings.

Glycerylnitrat is employed in several acute cardiovascular conditions where rapid vasodilation is required.

- Management of acute angina pectoris episodes - Treatment of acute heart failure with pulmonary congestion - Control of hypertensive emergencies resistant to standard therapy - Adjunct therapy during cardiac catheterisation procedures - Relief of coronary artery spasm (Prinzmetal angina)

Side effects of Glycerylnitrat vary in frequency and severity.

Common: - Headache, often described as throbbing - Flushing or warmth in the face and neck - Hypotension leading to dizziness or light‑headedness - Tachycardia or reflex heart rate increase - Nausea or mild gastrointestinal discomfort

Serious: - Severe hypotension with syncope - Methemoglobinemia, a rare blood disorder - Acute myocardial infarction precipitated by rapid blood pressure drop - Allergic reactions such as rash, itching, or anaphylaxis - Persistent chest pain unresponsive to therapy

When prescribing Glycerylnitrat, clinicians consider several safety factors.

- Assess baseline blood pressure; avoid use in patients with severe hypotension. - Use cautiously in patients with recent phosphodiesterase‑5 inhibitor use due to risk of profound hypotension. - Monitor for signs of methemoglobinemia, especially in patients with G6PD deficiency. - Adjust dose in elderly patients or those with hepatic impairment. - Ensure proper intravenous line placement to prevent extravasation and local tissue injury. - Educate patients about the possibility of headache and advise appropriate management.

Glycerylnitrat can interact with several drug classes, influencing its safety profile.

Avoid: - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) because combined use may cause severe hypotension. - Other potent vasodilators such as hydralazine or other nitrates, which increase the risk of additive blood pressure lowering. - Certain antihypertensive agents (e.g., ACE inhibitors, ARBs) when used concurrently without monitoring.

Use with caution: - Beta‑blockers, as they may mask tachycardia reflex. - Diuretics, which can exacerbate volume depletion and hypotension. - Alcohol, which may enhance vasodilatory effects. - General anaesthetics during surgery, requiring close haemodynamic monitoring.